For the year ending 2025-12-31, TCRX had -$26,283K decrease in cash & cash equivalents over the period. -$139,726K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -129,766 |
| Depreciation expense | 2,866 |
| Accretion of marketable securities | -2,409 |
| Non-cash interest expense related to loan payable | 462 |
| Stock-based compensation | 11,706 |
| Prepaid expenses and other assets | 525 |
| Right-of-use assets and lease liabilities, net | 2,909 |
| Accounts payable | -3,011 |
| Accrued expense and other liabilities | -7,226 |
| Deferred revenue | -10,325 |
| Net cash used in operating activities | -135,319 |
| Purchases of property and equipment | 4,407 |
| Purchases of marketable securities | 87,471 |
| Proceeds from maturities of marketable securities | 201,250 |
| Net cash provided by (used in) investing activities | 109,372 |
| Issuance of common stock under employee stock purchase plan | 264 |
| Cash paid for debt issuance costs | 400 |
| Cash paid for financing costs | 200 |
| Net cash provided by (used in) financing activities | -336 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -26,283 |
| Cash, cash equivalents, and restricted cash - beginning of year | 183,720 |
| Cash, cash equivalents, and restricted cash - end of year | 157,437 |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)